Financial Consulate’s 10x Genomics TXG Stock Holding History

Financial Consulate’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.84M	Sell	126,356 -30,101	-19%	-$789K	0.54%	22
2026 Q1	$3.32M	Hold	156,457	–	–	0.41%	25
2025 Q4	$2.55M	Hold	156,457	–	–	0.35%	28
2025 Q3	$1.83M	Buy	+156,457	New	+$2.04M	0.26%	31
2023 Q2	–	Sell	-156,457	Closed	-$8.73M	–	108
2023 Q1	$8.73M	Hold	156,457	–	–	3.05%	9
2022 Q4	$5.7M	Buy	156,457 +1,515	+1%	+$49.5K	1.99%	11
2022 Q3	$4.41M	Hold	154,942	–	–	1.86%	10
2022 Q2	$7.01M	Hold	154,942	–	–	3.29%	9
2022 Q1	$11.8M	Hold	154,942	–	–	4.53%	8
2021 Q4	$23.1M	Buy	154,942 +339	+0.2%	+$51.9K	8%	2
2021 Q3	$22.5M	Buy	154,603 +13,345	+9%	+$2.29M	8.16%	3
2021 Q2	$27.7M	Sell	141,258 -17,500	-11%	-$3.17M	9.97%	1
2021 Q1	$28.7M	Sell	158,758 -10,000	-6%	-$1.73M	11.65%	1
2020 Q4	$23.9M	Buy	168,758 +5,392	+3%	+$782K	10.31%	1
2020 Q3	$20.4M	Sell	163,366 -33,572	-17%	-$3.52M	9.67%	1
2020 Q2	$17.6M	Sell	196,938 -10,640	-5%	-$829K	8.94%	1
2020 Q1	$12.9M	Buy	+207,578	New	+$16.2M	7.68%	1

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Financial Consulate's TXG Position: Q2 2026 in Review

Financial Consulate reduced its 10x Genomics (TXG) stake by 19% in Q2 2026, selling an estimated $789K and leaving 126,356 shares worth $4.84M. The position accounts for 0.54% of the portfolio, ranked #22.

Financial Consulate first reported a position in TXG in Q1 2020 and has held it in 17 quarters since. The position peaked at $28.7M in Q1 2021. 391 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Financial Consulate held 126,356 shares of 10x Genomics worth $4.84M as of Q2 2026.
Financial Consulate sold 30,101 10x Genomics shares in Q2 2026, an estimated $789K.
10x Genomics made up 0.54% of Financial Consulate's portfolio in Q2 2026, its #22 holding.
Financial Consulate first reported a position in 10x Genomics in Q1 2020 and has held it in 17 quarters since.
Financial Consulate's 10x Genomics position peaked at $28.7M in Q1 2021.
391 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Financial Consulate's 13F filing for Q2 2026, filed 23 Jul 2026.